Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.

FBIO

Fortress Biotech (FBIO)

Fortress Biotech Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:FBIO
일자시간출처헤드라인심볼기업
2024/05/1621:30GlobeNewswire Inc.Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)NASDAQ:FBIOFortress Biotech Inc
2024/05/1621:00GlobeNewswire Inc.Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company ShowcaseNASDAQ:FBIOFortress Biotech Inc
2024/05/1605:15GlobeNewswire Inc.Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:FBIOFortress Biotech Inc
2024/05/1605:01GlobeNewswire Inc.Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company ShowcaseNASDAQ:FBIOFortress Biotech Inc
2024/05/1521:30GlobeNewswire Inc.Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:FBIOFortress Biotech Inc
2024/05/1421:30GlobeNewswire Inc.Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver TransplantationNASDAQ:FBIOFortress Biotech Inc
2024/05/1405:01GlobeNewswire Inc.Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:FBIOFortress Biotech Inc
2024/05/0721:30GlobeNewswire Inc.Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024NASDAQ:FBIOFortress Biotech Inc
2024/05/0305:01GlobeNewswire Inc.Mustang Bio Announces Closing of $4 Million Public OfferingNASDAQ:FBIOFortress Biotech Inc
2024/05/0205:01GlobeNewswire Inc.Journey Medical Corporation Appoints Joseph Benesch as Chief Financial OfficerNASDAQ:FBIOFortress Biotech Inc
2024/04/3009:00GlobeNewswire Inc.Mustang Bio Announces Pricing of $4 Million Public OfferingNASDAQ:FBIOFortress Biotech Inc
2024/04/2921:00GlobeNewswire Inc.Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross ProceedsNASDAQ:FBIOFortress Biotech Inc
2024/04/2521:30GlobeNewswire Inc.Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024NASDAQ:FBIOFortress Biotech Inc
2024/04/2420:30GlobeNewswire Inc.Avenue Therapeutics Announces Reverse Stock SplitNASDAQ:FBIOFortress Biotech Inc
2024/03/2905:05GlobeNewswire Inc.Fortress Biotech Reports 2023 Financial Results and Recent Corporate HighlightsNASDAQ:FBIOFortress Biotech Inc
2024/03/2822:00GlobeNewswire Inc.Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune DiseasesNASDAQ:FBIOFortress Biotech Inc
2024/03/2521:30GlobeNewswire Inc.Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024NASDAQ:FBIOFortress Biotech Inc
2024/03/2205:01GlobeNewswire Inc.Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:FBIOFortress Biotech Inc
2024/03/1905:05GlobeNewswire Inc.Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:FBIOFortress Biotech Inc
2024/03/1821:30GlobeNewswire Inc.Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of RosaceaNASDAQ:FBIOFortress Biotech Inc
2024/03/1521:30GlobeNewswire Inc.Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024NASDAQ:FBIOFortress Biotech Inc
2024/03/1521:15GlobeNewswire Inc.Avenue Therapeutics Receives Positive Listing Determination from NasdaqNASDAQ:FBIOFortress Biotech Inc
2024/03/1321:30GlobeNewswire Inc.Journey Medical Corporation to Participate in the 36th Annual ROTH ConferenceNASDAQ:FBIOFortress Biotech Inc
2024/03/1221:30GlobeNewswire Inc.Fortress Biotech to Participate in 36th Annual ROTH ConferenceNASDAQ:FBIOFortress Biotech Inc
2024/03/1121:30GlobeNewswire Inc.Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual MeetingNASDAQ:FBIOFortress Biotech Inc
2024/03/1121:00GlobeNewswire Inc.Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual MeetingNASDAQ:FBIOFortress Biotech Inc
2024/03/0721:30GlobeNewswire Inc.Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade GliomaNASDAQ:FBIOFortress Biotech Inc
2024/03/0422:30GlobeNewswire Inc.Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes DiseaseNASDAQ:FBIOFortress Biotech Inc
2024/02/2222:30GlobeNewswire Inc.Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence EpilepsyNASDAQ:FBIOFortress Biotech Inc
2024/01/1122:30GlobeNewswire Inc.Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:FBIOFortress Biotech Inc
 검색 관련기사 보기:NASDAQ:FBIO